We are using our novel application of gene silencing technologies to build a focused product pipeline to address unmet medical needs across numerous indications, beginning first with Oculopharyngeal Muscular Dystrophy (OPMD).
BB-301 is a clinical-stage agent currently in Phase 1b/2a trials for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is the lead pipeline program for Benitec, and early-stage clinical studies are being conducted.
